Table 1.
Group | ADT n = 15 | Control n = 15 |
---|---|---|
Age |
69.0 ± 5.3 y |
66.1 ± 6.2 y |
Education |
9th grade: 1 |
9th grade: 1 |
|
High School/GED: 5 |
High School/GED: 5 |
|
College 1-3 years: 3 |
College 1-3 years: 3 |
|
College graduate: 2 |
College graduate: 3 |
|
Post-graduate: 4 |
Post-graduate: 3 |
MMSE |
29.0 ± 1.3 |
29.5 ± 0.6 |
Cancer staging |
Stage II: 13 |
Stage I: 1 |
|
Stage III: 2 |
Stage II: 12 |
|
|
Stage III: 2 |
Local therapy |
Radiation 100% |
Radiation 26.7% |
|
|
Surgery 66.7% |
|
|
Surgery + Radiation 6.7% |
QOL at baseline |
115 ± 22 |
132 ± 18 |
QOL of life at 6 months |
110 ± 23 |
128 ± 21 |
Testosterone at 6 months | 0.14 ± 0.10 ng/ml | 2.84 ± 0.94 ng/ml |
Note: ADT: Androgen Deprivation Therapy; GED: General Education Development Test; MMSE: Mini Mental State Examination; QOL: FACT-P quality of life score; there is no difference between groups in age (t = 1.172, p = 0.588, two-sided two-sample t test); there is no difference between groups in MMSE score (t = 1.417, p = 0.167, two-sided two-sample t test); staging follows the current guidelines of the 2010 American Joint Committee on Cancer (AJCC) that include Gleason score in the staging; there is also no difference across the two time points in the change of QOL between groups (F = 0.056, p = 0.814, interaction, repeated measures analysis of variance).